Article Information
History
- March 18, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Surabhi B. Vora, MD, MPH1,*,
- Janet A. Englund, MD1,
- Indi Trehan, MD, MPH, DTM&H1,
- Alpana Waghmare, MD1,
- Ada Kong, PharmD2,
- Amanda Adler, BA3 and
- Danielle M. Zerr, MD, MPH1
- 1Department of Pediatrics, University of Washington, Seattle, WA
- 2Department of Pharmacy, Seattle Children’s Hospital, Seattle, WA
- 3Division of Infectious Diseases, Seattle Children’s Hospital, Seattle, WA
- ↵*Corresponding author:
Surabhi B. Vora, MD, MPH, Address: Seattle Children’s Hospital, 4800 Sand Point Way NE, Seattle, WA 98105, Email: surabhi.vora{at}seattlechildrens.org Phone: (206) 987-0119
Posted March 18, 2022.
Monoclonal antibody and antiviral therapy for treatment of mild-to-moderate COVID-19 in pediatric patients
